πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12280089

Dry powder formulation of caveolin-1 peptides and methods of use thereof

The Board of Regents of the University of Texas System Β· Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12280108

Vaccines having an antigen and interleukin-21 as an adjuvant

Inovio Pharmaceuticals, Inc. Β· Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12280113

Ras inhibitors

Revolution Medicines, Inc. Β· Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12274710

Compound for regulating body weight imbalance, composition thereof and application thereof

GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12274725

Zika virus strains for treatment of glioma

The Board of Regents of the University of Texas System Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12274735

IL-4-fusion formulations for treatment of central nervous system (CNS) tumors

Medicenna Therapeutics Inc. Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12274759

Affibody proteins specific for B7-H3 (CD276)

Regents of the University of Minnesota Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12274684

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

United Therapeutics Corporation Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12275684

Methods for making and using endoxifen

ATOSSA THERAPEUTICS, INC. Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12274696

Methods of administering nalbuphine

Trevi Therapeutics, Inc. Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12275685

Oligo-benzamide analogs and their use in cancer treatment

The Board of Regents of the University of Texas System Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12274723

Bacteriophage compositions and methods for treatment of bacterial infections

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12275758

Prefusion RSV F proteins and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12274741

Cattle fever tick-infestation vaccines and uses thereof

The United States of America, as represented by the Secretary of Agriculture Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12275966

Genetically engineered cells

The Regents of the University of California Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12275964

Variant type V CRISPR/Cas effector polypeptides and methods of use thereof

The Regents of the University of California Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12275957

Next generation designer liver organoids and their methods of preparation and use

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12275792

Antigen-binding proteins that activate the leptin receptor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12275781

Monoclonal antibodies against MHC-bound human dickkopf-1 peptides and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12275937

Stereospecific linkages in RNA editing oligonucleotides

ProQR Therapeutics II B.V. Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12275940

Conjugated antisense compounds and their use

Ionis Pharmaceuticals, Inc. Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12275769

Activatable interleukin 12 polypeptides and methods of use thereof

Werewolf Therapeutics, Inc. Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12275955

Combining iPSC derived effector cell types for immunotherapy use

Fate Therapeutics, Inc. Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12274747

Compositions and methods for treating cytokine release syndrome

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted